All News

The BCBSNC Foundation's focus on access to care, health through food, and youth mental health aligns with broader national health trends.

Based on their findings, the 2 experts suggested that tiered benefit design may already strongly influence consumer choices.

Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

The future of specialty pharmacy is not automation alone, but technology designed to assist patients through personalized support.

House lawmakers questioned hospital CEOs over rising health care costs, consolidation, opaque billing, Medicaid cuts, and site neutrality.

Behavioral text nudges outperformed nurse calls, boosting FIT completion by 9 percentage points at an FQHC while saving staff time.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

A 2-week sleep/light intervention shifted teens’ circadian timing earlier, increasing weeknight sleep by about 47 minutes in a randomized trial.

A multimodal AI approach could highlight areas in the brain that were associated with cognitive worsening in patients with MS.

OCM showed no increased likelihood of starting systemic therapy in patients with newly diagnosed cancers, despite gains in poor-prognosis cases.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

Community oncology delivers top-tier cancer care close to home, said Nicolas Ferreyros, COA, championing research, advocacy, and innovation to prove it.

COA’s Christine Pfaff, RPh, MBA, highlights clinical and operational innovation, AI adoption, and practice-sharing as keys to advancing community oncology care.

The ECHO study raises timely questions about whether managed care coverage policies have kept pace with evolving evidence.

The weekly anifrolumab autoinjector for systemic lupus erythematosus enables at-home use and improves convenience on top of standard therapy.

RSV vaccines and nirsevimab are linked to reduced infant hospitalizations, though seasonal spikes and data limitations remain concerns.

MASH cirrhosis carries high risks of death, decompensation, and liver cancer—especially with type 2 diabetes—while predictive tools remain limited.

The COA Community Oncology Conference will tackle AI, the rollout of bispecifics and CAR T in the community setting, plus reimbursement, radiation oncology, and patient access strategies.

Deuruxolitinib shows consistent efficacy across subgroups and drives early hair regrowth in severe alopecia areata, with gains seen by 8 weeks.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.

The benefits of exercise are particularly notable for patients who are dependent upon dialysis, a new review suggests.

The proposed rule on interoperability standards and prior authorization could lead to significant change in CMS.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.